

Introduced by Senator Figueroa

February 24, 2006

An act to amend Section 125001 of the Health and Safety Code, relating to public health.

LEGISLATIVE COUNSEL'S DIGEST

SB 1748, as introduced, Figueroa. Cystic fibrosis: newborn screening.

Existing law requires the State Department of Health Services to establish a program for the development, provision, and evaluation of genetic disease testing, and authorizes the department to provide laboratory testing facilities or make grants to, contract with, or make payments to, any laboratory that it deems qualified and cost-effective to conduct testing or with any metabolic specialty clinic to provide necessary treatment with qualified specialists. Existing law requires the department to expand statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, and organic acid disorders, and congenital adrenal hyperplasia, and requires the department to report to the Legislature regarding the progress of the program on or before July 1, 2006.

This bill would additionally require the department to expand statewide screening of newborns to include cystic fibrosis screening to detect cystic fibrosis as soon as possible. The bill would require the department, not later than July 1, 2007, to report to the Legislature on the progress of the program with respect to newborn screening for cystic fibrosis, including an estimate of the costs for screening, follow-up, and treatment as compared to costs and morbidity averted by this testing under the program.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

SECTION 1. Section 125001 of the Health and Safety Code is amended to read:

125001. (a) The department shall establish a program for the development, provision, and evaluation of genetic disease testing, and may provide laboratory testing facilities or make grants to, contract with, or make payments to, any laboratory that it deems qualified and cost-effective to conduct testing or with any metabolic specialty clinic to provide necessary treatment with qualified specialists. The program shall provide genetic screening and followup services for persons who have the screening.

(b) The department shall expand statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, and organic acid disorders ~~and~~, congenital adrenal hyperplasia, *and cystic fibrosis*, as soon as possible. The department shall provide information with respect to these disorders and available testing resources to all women receiving prenatal care and to all women admitted to a hospital for delivery. If the department is unable to provide this statewide screening by August 1, 2005, the department shall temporarily obtain these testing services through a competitive bid process from one or more public or private laboratories that meet the department's requirements for testing, quality assurance, and reporting. If the department determines that contracting for these services is more cost-effective, and meets the other requirements of this chapter, than purchasing the tandem mass spectrometry equipment themselves, the department shall contract with one or more public or private laboratories.

(c) (1) The department shall report to the Legislature regarding the progress of the program on or before July 1, 2006. The report shall include the costs for screening, ~~followup~~ *follow-up*, and treatment as compared to costs and morbidity averted for each condition tested for in the program.

(2) *The department shall report to the Legislature regarding the progress of the program with regard to implementing newborn screening for cystic fibrosis required pursuant to subdivision (b) on or before July 1, 2007. The report shall include the costs for screening, follow-up, and treatment as*

1 *compared to costs and morbidity averted by this testing under the*
2 *program.*

O